304 related articles for article (PubMed ID: 34181109)
1. PSMA: a game changer in the diagnosis and treatment of advanced prostate cancer.
Parsi M; Desai MH; Desai D; Singhal S; Khandwala PM; Potdar RR
Med Oncol; 2021 Jun; 38(8):89. PubMed ID: 34181109
[TBL] [Abstract][Full Text] [Related]
2. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
Farolfi A; Fendler W; Iravani A; Haberkorn U; Hicks R; Herrmann K; Walz J; Fanti S
Eur Urol Oncol; 2019 Mar; 2(2):152-162. PubMed ID: 31017091
[TBL] [Abstract][Full Text] [Related]
3. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
Barrio M; Fendler WP; Czernin J; Herrmann K
Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
[TBL] [Abstract][Full Text] [Related]
4.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
5. [PSMA-based theranostics for prostate cancer : From imaging to treatment].
Ilhan H; la Fougère C; Krause BJ
Urologe A; 2020 May; 59(5):617-625. PubMed ID: 32377764
[TBL] [Abstract][Full Text] [Related]
6. PSMA Ligands for PET Imaging of Prostate Cancer.
Schwarzenboeck SM; Rauscher I; Bluemel C; Fendler WP; Rowe SP; Pomper MG; Afshar-Oromieh A; Herrmann K; Eiber M
J Nucl Med; 2017 Oct; 58(10):1545-1552. PubMed ID: 28687599
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls.
Hofman MS; Hicks RJ; Maurer T; Eiber M
Radiographics; 2018; 38(1):200-217. PubMed ID: 29320333
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with
Ferraro DA; Rüschoff JH; Muehlematter UJ; Kranzbühler B; Müller J; Messerli M; Husmann L; Hermanns T; Eberli D; Rupp NJ; Burger IA
Theranostics; 2020; 10(14):6082-6094. PubMed ID: 32483440
[TBL] [Abstract][Full Text] [Related]
9. The utility of radiolabeled PSMA ligands for tumor imaging.
Shahrokhi P; Masteri Farahani A; Tamaddondar M; Rezazadeh F
Chem Biol Drug Des; 2022 Jan; 99(1):136-161. PubMed ID: 34472217
[TBL] [Abstract][Full Text] [Related]
10. Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of
Hofman MS; Eu P; Jackson P; Hong E; Binns D; Iravani A; Murphy D; Mitchell C; Siva S; Hicks RJ; Young JD; Blower PJ; Mullen GE
J Nucl Med; 2018 Apr; 59(4):625-631. PubMed ID: 28986512
[No Abstract] [Full Text] [Related]
11. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
12. A Prospective Comparison of
Harmon SA; Bergvall E; Mena E; Shih JH; Adler S; McKinney Y; Mehralivand S; Citrin DE; Couvillon A; Madan RA; Gulley JL; Mease RC; Jacobs PM; Pomper MG; Turkbey B; Choyke PL; Lindenberg ML
J Nucl Med; 2018 Nov; 59(11):1665-1671. PubMed ID: 29602821
[TBL] [Abstract][Full Text] [Related]
13. PSMA PET and Radionuclide Therapy in Prostate Cancer.
Bouchelouche K; Turkbey B; Choyke PL
Semin Nucl Med; 2016 Nov; 46(6):522-535. PubMed ID: 27825432
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.
Bandari RP; Jiang Z; Reynolds TS; Bernskoetter NE; Szczodroski AF; Bassuner KJ; Kirkpatrick DL; Rold TL; Sieckman GL; Hoffman TJ; Connors JP; Smith CJ
Nucl Med Biol; 2014 Apr; 41(4):355-63. PubMed ID: 24508213
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.
Aggarwal R; Wei X; Kim W; Small EJ; Ryan CJ; Carroll P; Cooperberg M; Evans MJ; Hope T
Eur Urol Oncol; 2018 May; 1(1):78-82. PubMed ID: 31100231
[TBL] [Abstract][Full Text] [Related]
16. Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer.
Ceci F; Castellucci P; Fanti S
Q J Nucl Med Mol Imaging; 2019 Mar; 63(1):7-18. PubMed ID: 29521482
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific membrane antigen targeted PET imaging for prostate cancer recurrence.
Ferdinandus J; Fendler WP; Hadaschik B; Herrmann K
Curr Opin Urol; 2020 Sep; 30(5):635-640. PubMed ID: 32732621
[TBL] [Abstract][Full Text] [Related]
18. New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy.
Haberkorn U; Eder M; Kopka K; Babich JW; Eisenhut M
Clin Cancer Res; 2016 Jan; 22(1):9-15. PubMed ID: 26728408
[TBL] [Abstract][Full Text] [Related]
19. The Effects of Monosodium Glutamate on PSMA Radiotracer Uptake in Men with Recurrent Prostate Cancer: A Prospective, Randomized, Double-Blind, Placebo-Controlled Intraindividual Imaging Study.
Harsini S; Saprunoff H; Alden T; Mohammadi B; Wilson D; Bénard F
J Nucl Med; 2021 Jan; 62(1):81-87. PubMed ID: 32385167
[TBL] [Abstract][Full Text] [Related]
20. Advances in prostate-specific membrane antigen PET of prostate cancer.
Bouchelouche K; Choyke PL
Curr Opin Oncol; 2018 May; 30(3):189-196. PubMed ID: 29465429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]